Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2023-09-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
海通证券股份有限公司关于奥锐特药业股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the listing and circulation of restricted shares from a company's initial public offering (IPO). It includes information about the types of restricted shares, shareholder commitments, shareholding changes, and compliance with relevant laws and regulations. The document does not present financial statements or earnings data, nor is it a transcript, presentation, or announcement of voting results. It is a regulatory compliance and verification report related to share listing and circulation. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and verification disclosure that does not fit other specific categories like capital updates or director dealings.
2023-09-14 Chinese
奥锐特药业股份有限公司首次公开发行部分限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is an official announcement regarding the listing and circulation of previously restricted shares following the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the lock-up period expiration, shareholder commitments, and regulatory approvals. The document includes specific dates, share quantities, shareholder names, and compliance statements from the sponsor institution. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. Instead, it is a formal announcement about the change in share status and circulation. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share circulation and compliance with lock-up agreements, not a financial report or capital raising update.
2023-09-14 Chinese
国浩律师（杭州）事务所关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券之补充法律意见书（二）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a company's issuance of convertible bonds to unspecified investors. It references specific legal and regulatory frameworks such as the Securities Law, Company Law, and various administrative measures related to convertible bonds. The document includes detailed legal compliance checks, approvals, qualifications, and conditions for the issuance, as well as corporate governance and financial data references. It is not a financial report, earnings release, or management discussion but a legal opinion supplement related to a capital raising activity. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it pertains to the issuance of convertible bonds and related legal compliance.
2023-09-12 Chinese
天健会计师事务所（特殊普通合伙）关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券申请文件的审核问询函中有关财务事项的说明（2023年半年度财务数据更新版）
Capital/Financing Update Classification · 95% confidence The document is a detailed financial and operational explanation related to a company's application for issuing convertible bonds to unspecified investors. It includes extensive financial data, investment breakdowns, cost estimations, and project descriptions. The text references a regulatory inquiry from the Shanghai Stock Exchange and includes detailed financial figures and projections related to the financing scale and benefits measurement. This indicates it is a regulatory filing related to financing activities, specifically a capital/financing update. The document is lengthy (15,000 characters) and contains substantive financial data, not just an announcement or certification. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-09-12 Chinese
关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券申请文件审核问询函的回复报告（2023年半年度财务数据更新版）
Capital/Financing Update Classification · 95% confidence The document is a detailed reply report to an inquiry letter from the Shanghai Stock Exchange regarding a company's application for issuing convertible bonds to unspecified investors. It contains extensive information about the company's fundraising project, including project necessity, financing scale, benefits, product details, market analysis, production capacity, technology, personnel, and risk measures. The document is lengthy (15,000 characters) and includes detailed financial and operational data related to the fundraising and capital investment projects. It is not a simple announcement or a brief summary but a comprehensive report addressing regulatory questions about a capital raising activity. Therefore, this document fits best into the category of Capital/Financing Update (CAP), as it provides updates and detailed information on the company's fundraising activities and related project implementation.
2023-09-12 Chinese
海通证券股份有限公司关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券之上市保荐书（2023年半年度财务数据更新版）
Capital/Financing Update Classification · 95% confidence The document is a detailed listing sponsorship letter (上市保荐书) issued by Haitong Securities Co., Ltd. regarding Aurisco Pharmaceutical Co., Ltd.'s issuance of convertible bonds to unspecified investors. It includes extensive information about the issuer's business, financial data, risk factors, issuance details, bond terms, interest calculation, and conversion price adjustments. The document is regulatory in nature, related to a capital market transaction (convertible bond issuance), and is not a typical financial report like an annual or interim report. It is not a brief announcement but a comprehensive sponsorship document required for the bond issuance process under Chinese securities regulations. This type of document fits best under the category of Capital/Financing Update (CAP), as it provides detailed updates on the company's fundraising and financing activities, specifically the issuance of convertible bonds.
2023-09-12 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.